Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

quotesThe approval of tucatinib is a first in many ways. Most importantly, it demonstrated a survival impr…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug

quotesThe FDA has approved a new formulation of Mitomycin C (MMC) in hydrogel (4 mg/ml) solution for insti…quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices

quotesPBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

ICER Presents Alternative Pricing Models for Remdesivir as a Treatment for COVID-19

quotesICER steps in to take advantage of “informing the public debate” (I did not know we were there y…quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

FDA Approves Olaparib For HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

quotesPAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patients. …quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

FDA Approves Olaparib For HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

quotesPAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patients. …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

GRAIL Announces Validation of its Multi-Cancer Early Detection Test Published in Annals of Oncology

quotesThe reported low false positive rate in this large validation data set and high diagnostic acumen fo…quotes

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

quotesThe approval of tucatinib is a first in many ways. Most importantly, it demonstrated a survival impr…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Roche’s Tecentriq Gains New First-line Lung Cancer Use

quotesWhile it's always nice to have another option, it's hard for me to see how atezolizumab provides any…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug

quotesThe FDA has approved a new formulation of Mitomycin C (MMC) in hydrogel (4 mg/ml) solution for insti…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Radiotherapy Can Be Used In Hard-to-treat Bladder Cancer

quotesRadiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance…quotes

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Stephen M. Schleicher, M.D., MBA

Community Oncology,
Medical Oncologist,
OneOncology

No comments to show!

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices

quotesPBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

New Medicare and Medicaid Waivers, Rule Changes Aim to Increase COVID-19 Testing and Support Health Care Workers

quotesThe increase in compensation for pure telephone visits is appreciated. The actual time and work for …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

ICER Presents Alternative Pricing Models for Remdesivir as a Treatment for COVID-19

quotesICER steps in to take advantage of “informing the public debate” (I did not know we were there y…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Roche’s Tecentriq Gains New First-line Lung Cancer Use

quotesWhile it's always nice to have another option, it's hard for me to see how atezolizumab provides any…quotes

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

GRAIL Announces Validation of its Multi-Cancer Early Detection Test Published in Annals of Oncology

quotesThe reported low false positive rate in this large validation data set and high diagnostic acumen fo…quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

New Medicare and Medicaid Waivers, Rule Changes Aim to Increase COVID-19 Testing and Support Health Care Workers

quotesThe increase in compensation for pure telephone visits is appreciated. The actual time and work for …quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Radiotherapy Can Be Used In Hard-to-treat Bladder Cancer

quotesRadiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance…quotes